Guardant Health, Inc. $GH Shares Bought by Janus Henderson Group PLC

Janus Henderson Group PLC raised its holdings in Guardant Health, Inc. (NASDAQ:GH) by 19.4% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 140,345 shares of the company’s stock after acquiring an additional 22,844 shares during the quarter. Janus Henderson Group PLC’s holdings in Guardant Health were worth $12,960,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. First Pacific Financial increased its position in shares of Guardant Health by 33.1% during the first quarter. First Pacific Financial now owns 559 shares of the company’s stock worth $52,000 after acquiring an additional 139 shares during the period. Xponance LLC boosted its holdings in Guardant Health by 2.1% in the fourth quarter. Xponance LLC now owns 9,630 shares of the company’s stock valued at $984,000 after purchasing an additional 199 shares during the period. Danske Bank A S boosted its holdings in Guardant Health by 20.0% in the fourth quarter. Danske Bank A S now owns 1,200 shares of the company’s stock valued at $123,000 after purchasing an additional 200 shares during the period. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna grew its stake in Guardant Health by 1.9% during the 4th quarter. Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna now owns 11,000 shares of the company’s stock worth $1,124,000 after purchasing an additional 200 shares in the last quarter. Finally, Wealthfront Advisers LLC grew its stake in Guardant Health by 7.2% during the 1st quarter. Wealthfront Advisers LLC now owns 3,042 shares of the company’s stock worth $281,000 after purchasing an additional 204 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Buying and Selling at Guardant Health

In other news, Director Musa Tariq sold 1,951 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $131.16, for a total transaction of $255,893.16. Following the sale, the director owned 11,048 shares of the company’s stock, valued at approximately $1,449,055.68. This trade represents a 15.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Brian Bell sold 2,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $128.62, for a total value of $257,240.00. Following the sale, the chief financial officer owned 47,509 shares of the company’s stock, valued at approximately $6,110,607.58. The trade was a 4.04% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 708,565 shares of company stock worth $90,556,597. 5.60% of the stock is currently owned by corporate insiders.

Guardant Health Price Performance

Shares of NASDAQ GH opened at $159.79 on Wednesday. The business has a 50-day moving average of $145.04 and a two-hundred day moving average of $114.14. The company has a market capitalization of $21.44 billion, a price-to-earnings ratio of -45.78 and a beta of 1.60. Guardant Health, Inc. has a 1 year low of $43.66 and a 1 year high of $176.58.

Analyst Ratings Changes

GH has been the topic of a number of analyst reports. UBS Group set a $150.00 price target on Guardant Health in a research report on Wednesday, June 24th. Mizuho boosted their price objective on Guardant Health from $175.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday. The Goldman Sachs Group restated a “buy” rating and set a $210.00 target price on shares of Guardant Health in a research note on Friday. JPMorgan Chase & Co. raised their target price on shares of Guardant Health from $185.00 to $195.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Finally, Stephens lifted their price target on shares of Guardant Health from $170.00 to $195.00 and gave the stock an “overweight” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and a consensus price target of $183.78.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.